CN114845723A - 包含喹唑啉衍生物或其盐的药物组合物 - Google Patents

包含喹唑啉衍生物或其盐的药物组合物 Download PDF

Info

Publication number
CN114845723A
CN114845723A CN202080071612.3A CN202080071612A CN114845723A CN 114845723 A CN114845723 A CN 114845723A CN 202080071612 A CN202080071612 A CN 202080071612A CN 114845723 A CN114845723 A CN 114845723A
Authority
CN
China
Prior art keywords
pharmaceutical composition
solid pharmaceutical
compound
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080071612.3A
Other languages
English (en)
Inventor
尚磊
何佳丽
晏彩霞
董平
周杰
孙迎迎
许易
陈智林
汤松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Pharmaceutical Holdings Beijing Co ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Capital Pharmaceutical Holdings Beijing Co ltd
Publication of CN114845723A publication Critical patent/CN114845723A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

一种包含喹唑啉衍生物或其可药用盐的固体药物组合物及其制备方法，具体而言涉及包含式(I)所示的N 6‑(1‑丙烯酰基氮杂环己烷‑4‑基)‑N 4‑(3‑氯‑4‑氟苯基)‑7‑甲氧基喹唑啉‑4,6‑二胺或其可药用盐的固体药物组合物、其制备方法及其用途。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080071612.3A 2019-11-01 2020-10-30 包含喹唑啉衍生物或其盐的药物组合物 Pending CN114845723A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911059476 2019-11-01
CN2019110594761 2019-11-01
PCT/CN2020/125383 WO2021083346A1 (zh) 2019-11-01 2020-10-30 包含喹唑啉衍生物或其盐的药物组合物

Publications (1)

Publication Number Publication Date
CN114845723A true CN114845723A (zh) 2022-08-02

Family

ID=75714903

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080071612.3A Pending CN114845723A (zh) 2019-11-01 2020-10-30 包含喹唑啉衍生物或其盐的药物组合物

Country Status (5)

Country Link
US (1) US20220395505A1 (zh)
EP (1) EP4052713A1 (zh)
JP (1) JP2023500315A (zh)
CN (1) CN114845723A (zh)
WO (1) WO2021083346A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678023A (zh) * 2007-06-07 2010-03-24 诺瓦提斯公司 甲磺酸伊马替尼的稳定的非晶形形式
WO2016150340A1 (zh) * 2015-03-20 2016-09-29 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
WO2018036539A1 (zh) * 2016-08-25 2018-03-01 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐的晶体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070190102A1 (en) * 2000-06-30 2007-08-16 Ping Luo Method of preparing hydroxyapatite based drug delivery implant for infection and cancer treatment
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
JP7296641B2 (ja) * 2017-12-19 2023-06-23 チェンドゥ・ジンルイ・ファウンデーション・バイオテック・カンパニー・リミテッド キナゾリン誘導体およびその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678023A (zh) * 2007-06-07 2010-03-24 诺瓦提斯公司 甲磺酸伊马替尼的稳定的非晶形形式
WO2016150340A1 (zh) * 2015-03-20 2016-09-29 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
WO2018036539A1 (zh) * 2016-08-25 2018-03-01 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐的晶体

Also Published As

Publication number Publication date
JP2023500315A (ja) 2023-01-05
WO2021083346A1 (zh) 2021-05-06
EP4052713A1 (en) 2022-09-07
US20220395505A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
AU2010316683A1 (en) Tablet formulations of neratinib maleate
EP2580206B1 (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
EP2635282A1 (en) Compositions and methods for treating myelofibrosis
CN112220770B (zh) 司来帕格的药物组合物及其制备方法
EP2540318B1 (en) Sustained-release solid preparation for oral use
JP2023027312A (ja) ５－クロロ－ｎ４－［２－（ジメチルホスホリル）フェニル］－ｎ２－｛２－メトキシ－４－［４－（４－メチルピペラジン－１－イル）ピペリジン－１－イル］フェニル｝ピリミジン－２，４－ジアミンを含む医薬製剤
CN106102744A (zh) 用于治疗异常细胞生长的组合物和方法
CN112843060A (zh) 一种取代丁烯酰胺药物组合物及其制备方法
CN113827576B (zh) 一种活性成分为草酸纳洛解的药物组合物及制备方法
EP3558300B1 (en) Solid pharmaceutical formulations of asimadoline
CN114845723A (zh) 包含喹唑啉衍生物或其盐的药物组合物
KR20150079449A (ko) 클로미프라민 함유 약학 조성물 및 이의 제조 방법
CA2998422A1 (en) Formulation having controlled, delayed release of active ingredient
EP3424500B1 (en) Pharmaceutical composition comprising famitinib
CN114727965B (zh) 一种jak激酶抑制剂药物组合物
KR20160038837A (ko) 오셀타미비어 함유 과립, 그 과립을 포함하는 캡슐제, 및 이들의 제조방법
KR101512895B1 (ko) 엔테카비어를 포함하는 약학적 조성물의 제조방법
TWI814468B (zh) 藥用組合物、其製備方法及用途
WO2021136089A1 (zh) 一种抗肿瘤药物组合物以及提高化合物的溶解度的方法
EP3977984A1 (en) Parp inhibitor pellet preparation and preparation process therefor
EP4205730A1 (en) Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
WO2021083347A1 (zh) 喹唑啉衍生物或其盐、或其药物组合物的用途
CN117241789A (zh) 药用组合物
TW202245786A (zh) 喹唑啉化合物及藥物組合物的應用
WO2023239337A1 (en) A pharmaceutical composition comprising palbociclib

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination